JP MORGAN/CALL/VERTEX PHARMACEUTICALS/425/0.1/17.01.25

JP MORGAN/CALL/VERTEX PHARMACEUTICALS/425/0.1/17.01.25 Stock

DE000JL10EF3

Market Closed - Börse Stuttgart 05:05:41 2024-06-26 EDT
7.41 ^EUR	-1.46%

Current month	+30.00%
1 month	+19.32%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/CALL/VERTEX PHARMACEUTICALS/425/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions	06-21	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-26	7.41	-1.46%
24-06-25	7.52	+4.44%
24-06-24	7.2	-3.10%
24-06-21	7.43	+6.45%
24-06-20	6.98	-0.85%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 05:05 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL10EF
ISIN	DE000JL10EF3
Date issued	2023-04-18
Strike	425 $
Maturity	2025-01-17 (205 Days)
Parity	10 : 1
Emission price	3.1 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	8.47 €
Lowest since issue	2.57 €
Delta	0.76x
Omega	4.440
Premium	6.72x
Gearing	5.86x
Moneyness	1.115
Difference Strike	-49 $
Difference Strike %	-11.53%
Spread	0.3 €
Spread %	3.89%
Theoretical value	7.570
Implied Volatility	32.51 %
Total Loss Probability	32.50 %
Intrinsic value	4.589
Present value	2.981
Break even	505.83 €
Theta	-0.09x
Vega	0.1x
Rho	0.15x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

474 USD

Average target price

465.5 USD

Spread / Average Target

-1.79%

Consensus